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Ribonuclease 7:  
a new urinary 
antimicrobial peptide
Many epithelia exposed to the external 
environment (skin, gastrointestinal tract, 
and so on) secrete antimicrobial peptides 
that function in controlling the flora of 
these compartments. Bacteria normally 
appear at least transiently in the urine as 
a consequence of the frequent appear-
ance of bacteria in the blood. Spencer et 
al. identify ribonuclease 7 (RNase 7) as 
one antimicrobial peptide secreted by the 
kidney to presumably combat the tran-
sient bacteriuria. RNase 7 is known to 
be secreted by the skin, and the authors 
show that its mRNA is expressed by the 
kidney and bladder. Using immunofluo-
rescence, they showed that RNase 7 is 
present in the urothelium, the ureter, 
and the intercalated cells of the collecting 
tubules. The concentration of the protein 
in the urine was quite substantial, being 
in the micromolar range, a concentration 
capable of having sufficient antimicrobial 
activity against Gram-negative and 
Gram-positive uropathogenic bacteria. 
See page 174.
Warfarin nephropathy
The use of warfarin for anticoagulation 
is one of the mainstays of medical prac-
tice. However, recent concerns about 
its role in reducing vitamin K, which in 
turn might induce a number of previ-
ously unrecognized side effects, have 
increased the vigilance of investiga-
tors. The use of warfarin has nucleated 
new fields of research, including drug 
interaction studies and, more recently, 
pharmacogenomics. It is not rare that 
its use causes the international normal-
ized ratio (INR) to occasionally achieve 
higher levels than recommended, and 
these higher levels have been suggested 
to cause renal disease. In previous stud-
ies, Brodsky and colleagues monitored 
a large cohort of patients with chronic 
kidney disease (CKD) whose INR 
transiently reached 3 or higher. They 
noted that such patients often had an 
unexplained acute rise in serum cre-
atinine and an accelerated progression 
of CKD. Kidney biopsies of a subset 
of these patients showed intratubular 
obstruction by red blood cell casts. As 
they report in this issue, the authors 
studied patients without CKD who had 
at one time had an INR greater than 3 
and found that as many as 16% of the 
no-CKD cohort developed elevations of 
serum creatinine, compared with 33% of 
the CKD cohort. Thus, warfarin-related 
nephropathy may be a common compli-
cation of warfarin therapy in high-risk 
patients, and CKD doubles this risk. The 
mechanisms of these risks are unclear. 
See page 181.
Advanced glycation end 
products, obesity, and 
chronic kidney disease
Advanced glycation end products 
(AGEs) are produced as a consequence 
of a variety of endogenous oxidative 
reactions, and they also are produced by 
cooking and cause browning of foods. 
AGEs thus produced can be absorbed 
from the gastrointestinal tract; hence 
their ingestion may compound the 
effects of endogenous AGEs produced 
presumably by oxidative stress. Har-
court et al. changed the diet of obese 
individuals (body mass index >26) for 
2 weeks, comparing high-AGE to low-
AGE diets. They found that renal func-
tion and inflammatory mediators were 
improved on the low-AGE diets. They 
also treated mice with alagebrium, a 
drug that reduces AGEs in mice with the 
receptor for AGE (RAGE) deleted when 
they are fed a high-AGE, high-fat diet. 
They found that the treatment improved 
urinary albumin excretion, creatinine 
clearance, inflammatory profile, and 
renal oxidative stress. Alagebrium treat-
ment resulted in decreased weight gain 
and improved glycemic control in com-
parison with wild-type mice on a high-
fat Western diet. Hence, reduced intake 
of AGEs may improve renal function in 
obesity. See page 190. 
